TY - JOUR AU - Murphy, J. AU - Coster, G. PY - 1997 DA - 1997// TI - Issues in patient compliance JO - Drugs VL - 54 UR - https://doi.org/10.2165/00003495-199754060-00002 DO - 10.2165/00003495-199754060-00002 ID - Murphy1997 ER - TY - JOUR AU - Osterberg, L. AU - Blaschke, T. PY - 2005 DA - 2005// TI - Adherence to medication JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMra050100 DO - 10.1056/NEJMra050100 ID - Osterberg2005 ER - TY - JOUR AU - Simpson, S. H. AU - Eurich, D. T. AU - Majumdar, R. AU - Padwal, R. S. AU - Tsuyuki, R. T. AU - Varney, J. AU - Johnson, J. A. PY - 2006 DA - 2006// TI - A meta-analysis of the association between adherence to drug therapy and mortality JO - BMJ VL - 333 UR - https://doi.org/10.1136/bmj.38875.675486.55 DO - 10.1136/bmj.38875.675486.55 ID - Simpson2006 ER - TY - JOUR AU - Kardas, P. AU - Lewek, P. AU - Matyjaszczyk, M. PY - 2013 DA - 2013// TI - Determinants of patient adherence: a review of systematic reviews JO - Front Pharmacol VL - 4 UR - https://doi.org/10.3389/fphar.2013.00091 DO - 10.3389/fphar.2013.00091 ID - Kardas2013 ER - TY - BOOK PY - 2003 DA - 2003// TI - Adherence to Long-term Therapies: Evidence for Action ID - ref5 ER - TY - JOUR AU - Claxton, A. J. AU - Cramer, J. AU - Pierce, C. PY - 2001 DA - 2001// TI - A systematic review of the associations between dose regimens and medication compliance JO - Clin Ther VL - 23 UR - https://doi.org/10.1016/S0149-2918(01)80109-0 DO - 10.1016/S0149-2918(01)80109-0 ID - Claxton2001 ER - TY - JOUR AU - Richter, A. AU - Anton, S. F. AU - Koch, P. AU - Dennett, S. L. PY - 2003 DA - 2003// TI - The impact of reducing dose frequency on health outcomes JO - Clin Ther VL - 25 UR - https://doi.org/10.1016/S0149-2918(03)80222-9 DO - 10.1016/S0149-2918(03)80222-9 ID - Richter2003 ER - TY - JOUR AU - Ridwan, E. AU - Schultink, W. AU - Dillon, D. AU - Gross, R. PY - 1996 DA - 1996// TI - Effects of weekly iron supplementation on pregnant Indonesian women are similar to those of daily supplementation JO - Am J Clin Nutr VL - 63 UR - https://doi.org/10.1093/ajcn/63.6.884 DO - 10.1093/ajcn/63.6.884 ID - Ridwan1996 ER - TY - JOUR AU - Lipton, R. B. AU - Stewart, W. F. AU - Diamond, S. AU - Diamond, M. L. AU - Reed, M. PY - 2001 DA - 2001// TI - Prevalence and burden of migraine in the United States: data from the American migraine study II JO - Headache VL - 41 UR - https://doi.org/10.1046/j.1526-4610.2001.041007646.x DO - 10.1046/j.1526-4610.2001.041007646.x ID - Lipton2001 ER - TY - JOUR AU - Dodick, D. W. AU - Silberstein, S. D. AU - Bigal, M. E. AU - Yeung, P. P. AU - Goadsby, P. J. AU - Blankenbiller, T. PY - 2018 DA - 2018// TI - Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial JO - JAMA VL - 319 UR - https://doi.org/10.1001/jama.2018.4853 DO - 10.1001/jama.2018.4853 ID - Dodick2018 ER - TY - STD TI - AIMOVIG™ [prescribing information]. Thousand Oaks, CA: Amgen; 2018 ID - ref11 ER - TY - STD TI - AJOVY® [prescribing information]. North Wales, PA: Teva Pharmaceuticals; 2018 ID - ref12 ER - TY - STD TI - EMGALITY® [prescribing information]. Indianapolis, IN: Eli Lilly; 2018 ID - ref13 ER - TY - JOUR AU - Skljarevski, V. AU - Matharu, M. AU - Millen, B. A. AU - Ossipov, M. H. AU - Kim, B. K. AU - Yang, J. Y. PY - 2018 DA - 2018// TI - Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial JO - Cephalalgia VL - 38 UR - https://doi.org/10.1177/0333102418779543 DO - 10.1177/0333102418779543 ID - Skljarevski2018 ER - TY - JOUR AU - Silberstein, S. D. AU - Dodick, D. W. AU - Bigal, M. E. AU - Yeung, P. P. AU - Goadsby, P. J. AU - Blankenbiller, T. PY - 2017 DA - 2017// TI - Fremanezumab for the preventive treatment of chronic migraine JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1709038 DO - 10.1056/NEJMoa1709038 ID - Silberstein2017 ER - TY - JOUR AU - Dodick, D. W. AU - Ashina, M. AU - Brandes, J. L. AU - Kudrow, D. AU - Lanteri-Minet, M. AU - Osipova, V. PY - 2018 DA - 2018// TI - ARISE: a phase 3 randomized trial of erenumab for episodic migraine JO - Cephalalgia VL - 38 UR - https://doi.org/10.1177/0333102418759786 DO - 10.1177/0333102418759786 ID - Dodick2018 ER - TY - STD TI - BOTOX® [prescribing information]. Madison, NJ: Allergan; 2018 ID - ref17 ER - TY - JOUR AU - Diener, H. C. AU - Charles, A. AU - Goadsby, P. J. AU - Holle, D. PY - 2015 DA - 2015// TI - New therapeutic approaches for the prevention and treatment of migraine JO - Lancet Neurol VL - 14 UR - https://doi.org/10.1016/S1474-4422(15)00198-2 DO - 10.1016/S1474-4422(15)00198-2 ID - Diener2015 ER - TY - JOUR AU - Hepp, Z. AU - Dodick, D. W. AU - Varon, S. F. AU - Chia, J. AU - Matthew, N. AU - Gillard, P. PY - 2017 DA - 2017// TI - Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis JO - Cephalalgia VL - 37 UR - https://doi.org/10.1177/0333102416678382 DO - 10.1177/0333102416678382 ID - Hepp2017 ER - TY - JOUR AU - Blumenfeld, A. M. AU - Bloudek, L. M. AU - Becker, W. J. AU - Buse, D. C. AU - Varon, S. F. AU - Maglinte, G. A. PY - 2013 DA - 2013// TI - Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II) JO - Headache VL - 53 UR - https://doi.org/10.1111/head.12055 DO - 10.1111/head.12055 ID - Blumenfeld2013 ER - TY - JOUR AU - Hepp, Z. AU - Dodick, D. W. AU - Varon, S. F. AU - Gillard, P. AU - Hansen, R. N. AU - Devine, E. B. PY - 2015 DA - 2015// TI - Adherence to oral migraine-preventive medications among patients with chronic migraine JO - Cephalalgia VL - 35 UR - https://doi.org/10.1177/0333102414547138 DO - 10.1177/0333102414547138 ID - Hepp2015 ER - TY - JOUR AU - Holroyd, K. A. AU - Drew, J. B. AU - Cottrell, C. K. AU - Romanek, K. M. AU - Heh, V. PY - 2007 DA - 2007// TI - Impaired functioning and quality of life in severe migraine: the role of catastrophizing and associated symptoms JO - Cephalalgia VL - 27 UR - https://doi.org/10.1111/j.1468-2982.2007.01420.x DO - 10.1111/j.1468-2982.2007.01420.x ID - Holroyd2007 ER - TY - JOUR AU - Radat, F. AU - Swendsen, J. PY - 2005 DA - 2005// TI - Psychiatric comorbidity in migraine: a review JO - Cephalalgia VL - 25 UR - https://doi.org/10.1111/j.1468-2982.2004.00839.x DO - 10.1111/j.1468-2982.2004.00839.x ID - Radat2005 ER - TY - JOUR AU - Peres, M. F. AU - Silberstein, S. AU - Moreira, F. AU - Corchs, F. AU - Vieira, D. S. AU - Abraham, N. PY - 2007 DA - 2007// TI - Patients' preference for migraine preventive therapy JO - Headache VL - 47 UR - https://doi.org/10.1111/j.1526-4610.2007.00757.x DO - 10.1111/j.1526-4610.2007.00757.x ID - Peres2007 ER - TY - JOUR AU - Mitsikostas, D. D. AU - Belesioti, I. AU - Arvaniti, C. AU - Mitropoulou, E. AU - Deligianni, C. AU - Kasioti, E. PY - 2017 DA - 2017// TI - Patients' preferences for headache acute and preventive treatment JO - J Headache Pain VL - 18 UR - https://doi.org/10.1186/s10194-017-0813-3 DO - 10.1186/s10194-017-0813-3 ID - Mitsikostas2017 ER - TY - JOUR AU - Arroyo, E. AU - Grau, C. AU - Ramo-Tello, C. AU - Parra, J. AU - Sanchez-Solino, O. PY - 2011 DA - 2011// TI - GAP study group. Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project JO - Eur Neurol VL - 65 UR - https://doi.org/10.1159/000323216 DO - 10.1159/000323216 ID - Arroyo2011 ER - TY - JOUR AU - Devonshire, V. AU - Lapierre, Y. AU - Macdonell, R. AU - Ramo-Tello, C. AU - Patti, F. AU - Fontoura, P. PY - 2011 DA - 2011// TI - The global adherence project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis JO - Eur J Neurol VL - 18 UR - https://doi.org/10.1111/j.1468-1331.2010.03110.x DO - 10.1111/j.1468-1331.2010.03110.x ID - Devonshire2011 ER - TY - JOUR AU - Treadaway, K. AU - Cutter, G. AU - Salter, A. AU - Lynch, S. AU - Simsarian, J. AU - Corboy, J. PY - 2009 DA - 2009// TI - Factors that influence adherence with disease-modifying therapy in MS JO - J Neurol VL - 256 UR - https://doi.org/10.1007/s00415-009-0096-y DO - 10.1007/s00415-009-0096-y ID - Treadaway2009 ER - TY - JOUR AU - Burstein, R. AU - Jakubowski, M. AU - Rauch, S. D. PY - 2011 DA - 2011// TI - The science of migraine JO - J Vestib Res VL - 21 ID - Burstein2011 ER - TY - JOUR AU - Sajatovic, M. AU - Ross, R. AU - Legacy, S. N. AU - Byerly, M. AU - Kane, J. M. AU - DiBiasi, F. PY - 2018 DA - 2018// TI - Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2 JO - Neuropsychiatr Dis Treat VL - 14 UR - https://doi.org/10.2147/NDT.S167485 DO - 10.2147/NDT.S167485 ID - Sajatovic2018 ER -